Shanghai Pharmaceutical To Focus Fully On Drug Distribution
This article was originally published in PharmAsia News
Shanghai Pharmaceutical Co., Ltd. has announced that it will withdraw from drug R&D and concentrate its resources on drug distribution, a business it has been leading domestically for nine years. The company will transfer its 19.66 percent stake in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and inject 6.5 million yuan to its holding company Shanghai Waigaoqiao Pharmaceutical Business And Distribution Center. However, Shanghai Pharmaceutical will not give up its original equipment manufacturing business, which gives a return on investment of 27.5 percent. It will renovate Tianping Pharmaceutical Factory's machining workshop to carry out OEM for U.S. Perrigo. (Click here for more - Chinese Language)
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.